- Home
- ILPT vs CRDF Comparison
ILPT vs CRDF Comparison
Compare ILPT & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILPT
- CRDF
- Stock Information
- Founded
- ILPT 2017
- CRDF 1999
- Country
- ILPT United States
- CRDF United States
- Employees
- ILPT N/A
- CRDF N/A
- Industry
- ILPT Real Estate Investment Trusts
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ILPT Real Estate
- CRDF Health Care
- Exchange
- ILPT Nasdaq
- CRDF Nasdaq
- Market Cap
- ILPT 174.6M
- CRDF 196.2M
- IPO Year
- ILPT 2018
- CRDF N/A
- Fundamental
- Price
- ILPT $3.09
- CRDF $2.63
- Analyst Decision
- ILPT Buy
- CRDF Strong Buy
- Analyst Count
- ILPT 2
- CRDF 4
- Target Price
- ILPT $10.00
- CRDF $12.00
- AVG Volume (30 Days)
- ILPT 359.8K
- CRDF 1.1M
- Earning Date
- ILPT 04-29-2025
- CRDF 05-20-2025
- Dividend Yield
- ILPT 1.28%
- CRDF N/A
- EPS Growth
- ILPT N/A
- CRDF N/A
- EPS
- ILPT N/A
- CRDF N/A
- Revenue
- ILPT $441,992,000.00
- CRDF $683,000.00
- Revenue This Year
- ILPT $8.07
- CRDF N/A
- Revenue Next Year
- ILPT N/A
- CRDF N/A
- P/E Ratio
- ILPT N/A
- CRDF N/A
- Revenue Growth
- ILPT 0.61
- CRDF 39.96
- 52 Week Low
- ILPT $2.45
- CRDF $2.01
- 52 Week High
- ILPT $5.45
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- ILPT 56.53
- CRDF 41.22
- Support Level
- ILPT $2.77
- CRDF $2.42
- Resistance Level
- ILPT $3.15
- CRDF $2.87
- Average True Range (ATR)
- ILPT 0.18
- CRDF 0.18
- MACD
- ILPT 0.08
- CRDF 0.01
- Stochastic Oscillator
- ILPT 91.85
- CRDF 24.42
About ILPT Industrial Logistics Properties Trust of Beneficial Interest
Industrial Logistics Properties Trust is a real estate investment trust. It owns and leases industrial and logistics properties throughout the United States. The company's investment portfolio includes industrial lands in Hawaii and industrial and logistics properties in other states. Rental revenue is earned from Hawaii Properties and Mainland Properties.
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.